Achillion Pharmaceuticals
Investor Relations Department
300 George St.
New Haven, CT 06511
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: ACHN	
Last Trade:	3.41
Trade Time:	4:15 PM ET Apr 28, 2017
Change:	-0.01 (-0.292%)
Day Range	3.36 - 3.44
52-Week Range	3.15 - 10.06
Volume	694,127

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

… (more)

Stock Performance



Press Releases [View all]

Apr 22, 2017
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178

Apr 6, 2017
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria

Mar 21, 2017
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors

Feb 28, 2017
Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London

Feb 23, 2017
Achillion Reports 2016 Fourth Quarter and Year-End Financial Results

Financial Disclosures [View all]

Fourth Quarter Financial Results

Feb 23, 2017
Annual Report (10-K)

Apr 17, 2017
Proxy Statement (DEF 14A)

Nov 3, 2016
Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)

May 3, 2016
Quarterly Report (10-Q)